
- BioPharm International-11-01-2017
- Volume 30
- Issue 11
FDA Overhauls Inspection Process and Field Operations
FDA seeks to focus on problematic facilities and inform firms quickly about site problems.
To ensure the quality and safety of drugs, biologics, and medical products more efficiently and effectively, FDA is making significant changes in its plant inspection program, including more attention to imports and to foreign producers of drugs for American consumers. An aim is to target manufacturing oversight to more high-risk operations and free up resources for greater scrutiny of foreign facilities in the process. Agency officials also seek to better coordinate and clarify the roles of field investigators and staff from FDA’s Center for Drug Evaluation and Research (CDER) (as well as other agency review centers) in selecting sites, weighing compliance action, and communicating inspection findings to firms. And increased FDA collaboration with foreign regulatory inspectorates promises to reduce redundant site visits and increase oversight of violative situations.
Field realignment
After several years of planning, FDA’s Office of Regulatory Affairs (ORA), which manages the agency’s 5000 field inspectors, officially implemented its Program Alignment (PA) initiative in May 2017. This major reorganization shifts ORA from a geographically-based inspection operation to a program aligned by commodities and vertically integrated, with more specialized investigators able to identify and provide more timely information on critical manufacturing issues. Specialized
Drugs regulated by CDER and the Center for Veterinary Medicine (CVM), for example, are managed by the Office of Pharmaceutical Quality Operations (OPQO), directed by long-time ORA official Alonza Cruse. He oversees four divisions of pharmaceutical quality operations, each headed by a regional manager, plus a division for quality programs (for compounders and preapproval inspections) and a division for foreign inspections, Cruse explained at the PDA/FDA regulatory conference in September 2017. The aim is to achieve more consistent and timely inspections with reduced uncertainty for industry.
Similarly, ORA’s Office of Biological Products Operations, headed by Ginette Michaud, has two operating divisions to oversee the production of blood products, tissues, vaccines, and other products regulated by the Center for Biologics Evaluation and Research (CBER). The Office of Bioresearch Monitoring Operations under Chrissy Cochran also has two divisions, while the Office of Medical Devices and Radiological Health Operations has three divisions.
A key goal of the reorganization is to enhance communication and collaboration between field inspectors and center product specialists. This approach for drugs is spelled out in a “Concept of Operations”
For preapproval inspections (PAIs), a CDER team, including staffers from the Office of Process and Facilities (OPF) in the Office of Product Quality (OPQ), prepares an integrated quality assessment. This assessment reviews information in an application on facilities, processes, and microbiology, plus past inspection reports, to determine whether a PAI is needed for each site listed in the submission. ORA leads any necessary inspection, with CDER participation, and communicates findings to the assessment team. A similar process is involved in planning for and conducting post-approval facility inspections, which may occur following manufacturing changes, particularly for a facility where a PAI has not taken place.
For GMP surveillance inspections, OPQ’s Office of Surveillance (OS) collaborates with ORA to determine the need, timing, and scope of site visits, based on a facility’s inspection history, type of products produced, and risks previously reported. ORA investigators generally conduct these inspections, informing CDER’s Office of Compliance (OC) if they observe questionable situations. ORA also leads for-cause inspections, interacting with CDER’s OPQ and OC.
To ensure timely inspections of facilities listed in new drug applications, FDA and industry agreed in the new prescription drug user fee program to delay application approval if a sponsor fails to identify all relevant sites in a submission. The aim is to provide complete facility information for ORA to have sufficient time to inspect and evaluate relevant production sites. The Generic Drug User Fee Amendments (GDUFA II) further establish a pre-submission correspondence process that requires manufacturers of critical drugs qualifying for priority approval to submit information on planned production facilities two months before filing the application-again, to support timely inspection of relevant production sites in tight timeframes.
A more efficient field inspection program also aims to communicate inspection findings to manufacturers more quickly. GDUFA II specifies that FDA will provide surveillance inspection findings to facility owners within 90 days of completing a site visit, beginning October 2018, and CDER officials expect to apply that goal to all drugs. The aim is for ORA to submit recommendations to CDER within 45 days of post-approval and surveillance inspections so that staff can follow up quickly with the manufacturer.
International collaboration
The need to oversee the growing number of overseas pharmaceutical manufacturers also is prompting US and European regulatory authorities to collaborate more on drug inspection activities. FDA and the European Medicines Agency (EMA) are moving forward with a Mutual Recognition Agreement (MRA) that will permit participants to rely more on each other’s inspection reports. By reducing the need to inspect all of more than 1000 registered drug production facilities in Europe, FDA would avoid duplicate site visits and free up resources to support greater oversight of firms in China, India, and other nations.
US and EU officials signed an
The current MRA initiative applies to GMP surveillance inspections for most drugs and biotech therapies, but could be extended to vaccines and veterinary products in the future. An important side-benefit of the final agreement may be to end EU batch inspection of US-made products shipped to Europe. In the future, pre-approval inspections might be covered in certain situations, prompting FDA and EU officials to examine how PAIs differ or are the same in the two regions. FDA’s need to complete such inspections in limited timeframes could lead to an agreement that permits
References
1. FDA,
2. FDA,
3. S. Gottlieb, “New Steps to Strengthen FDA’s Inspection And Oversight Of Drug Manufacturing,”
4. FDA, “Mutual Recognition Promises New Framework for Pharmaceutical Inspections for United States and European Union,”
5. FDA,
6. FDA,
Article Details
BioPharm International
Volume 30, Number 11
November 2017
Pages: 8-9
Citation
When referring to this article, please cite it as J. Wechsler, “FDA Overhauls Inspection Process and Field Operations," BioPharm International 30 (11) 2017.
Articles in this issue
almost 8 years ago
Connector Integrity in Single-Use Biomanufacturing Systemsalmost 8 years ago
ADC Development Robust Despite Lackluster Performancealmost 8 years ago
Change Control for Standard Operating Proceduresalmost 8 years ago
CDMO Acquisitions Build Strategic Supplier Basealmost 8 years ago
Pump Head for Shear-Sensitive Pumpingalmost 8 years ago
Dip-Molded Plastisol Y Connectorsalmost 8 years ago
Analytical Data System Updatealmost 8 years ago
Temperature-Controlled Shipping Solutionalmost 8 years ago
Evaluating Surface Cleanliness Using a Risk-Based Approachalmost 8 years ago
Awards Recognize Bio/Pharma Industry ContributionsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.